(Q24241239)

1

0 references

James Mason

object named as

James Mason

2

0 references

author name string

Gordon Dooley

4

0 references

Gladys Edwards

Cochrane Database of Systematic Reviews

5

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A double-blind comparison of 0.1% dithranol in a 17% urea base (‘Psoradrate’) and base alone in the treatment of active chronic psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Rationale for use and clinical responsiveness of hexafluoro-1,25-dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Tacrolimus ointment is effective for facial and intertriginous psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Fluocinolone acetonide topical oil for scalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Betamethasone valerate foam for treatment of nonscalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Biologics for chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Electronic monitoring of medication adherence in skin disease: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The pathophysiology of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Recognition and treatment of psoriasis. Special considerations in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical tacrolimus and pimecrolimus are not associated with skin atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Relapse, rebound, and psoriasis adverse events: an advisory group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Better medication adherence results in greater improvement in severity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Interventions for chronic palmoplantar pustulosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The response of psoriasis to betamethasone valerate and clobetasol propionate. A 6-month controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

21 January 2018

The course of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The economic impact of psoriasis increases with psoriasis severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

21 January 2018

Coping with psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Current severe psoriasis and the rule of tens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Emollients, moisturizers, and keratolytic agents in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

How patients experience psoriasis: results from a European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Immunopathogenesis and role of T cells in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Adherence to treatment in patients with psoriasis vulgaris: Turkish experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The immunological basis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Psoriasis: future research needs and goals for the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Adverse effects of topical glucocorticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The approach to psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Corticosteroid skin atrophogenicity: assessment methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Pharmionics in dermatology: a review of topical medication adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Economic evaluation of new drug therapies in terms of improved life quality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Topical preparations for the treatment of psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The importance of accurate dosage of topical agents: a method of estimating involved area and application to calcipotriol treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Antistreptococcal interventions for guttate and chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Allergic contact dermatitis from calcipotriol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Long-term use of topical calcipotriol in chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Adherence to treatment in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

HL-A in psoriasis vulgaris and in pustular psoriasis--population and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Histometric assessment of psoriatic plaques treated by vitamin D3 derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Combinations and comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Calcipotriol cream in the morning and ointment in the evening: a novel regimen to improve compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Interventions for nail psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Traditional Chinese herbs for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Quality of life in 6497 Nordic patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

Objective assessment of compliance with psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Natural history of psoriasis in 61 twin pairs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Tachyphylaxis to the Action of Topically Applied Corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Psoriasis in an Unselected Series of Twins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical fluocinonide and tachyphylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Failure of topical polymyxin B to improve mild plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Interventions for guttate psoriasis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

[Mometasone and calcipotriol optimize the initial therapeutic effect of dithranol in chronic persistent psoriasis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical treatments in psoriasis: today and tomorrow

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Adherence to topical therapy increases around the time of office visits

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Corneodesmosin (MHC S) gene in guttate psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Pathogenesis and clinical features of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

1 reference

7 January 2021

A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Once-daily treatment of psoriasis with topical glucocorticosteroid ointments

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

1 reference

7 January 2021

The prevalence of psoriasis in the Mongoloid race

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Preatrophy: covert sign of thinned skin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical calcipotriol in childhood psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Epidemiology of psoriasis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Additional studies on psoriasis in the tropics and in starvation camps.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Evidence that a locus for familial psoriasis maps to chromosome 4q

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Treatment of psoriasis with topical NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Stigmatization and psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Vitamin D Receptor Polymorphism and Calcipotriol Response in Patients with Psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Histocompatibility (HL-A) Antigens Associated with Psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A retrospective study of the teratogenicity of dermatological coal tar products

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

The genetics of psoriasis: a complex disorder of the skin and immune system

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Treatment of mild to moderate psoriasis with Reliéva, a Mahonia aquifolium extract--a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Treatment of psoriasis and atopic dermatitis with halcinonide cream applied once and three times daily

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A double-blind study of topical 1 alpha,25-dihydroxyvitamin D3 in psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Urine calcium excretion during treatment of psoriasis with topical calcipotriol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Highly purified omega-3-polyunsaturated fatty acids for topical treatment of psoriasis. Results of a double-blind, placebo-controlled multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

The effect of severe psoriasis on the quality of life of 369 patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Once daily vs. twice daily applications of topical treatments in psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A classification of psoriasis vulgaris according to phenotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Folate with methotrexate: big benefit, questionable cost

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Basement membrane changes in psoriatic patients on long-term topical corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Topical fish oil in psoriasis--a controlled and blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

High dose topical calcipotriol consistently reduces serum parathyroid hormone levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A comparison of single and multiple applications of halcinonide cream

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Joint complaints in psoriasis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Effectiveness of kukui nut oil as a topical treatment for psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Psoriasis: consensus on topical therapies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Evaluation of topical drug treatment in psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Patient compliance and disease management in the treatment of psoriasis in the Netherlands

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

An update on vitamin D3 analogues in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Intermittent Corticosteroid Maintenance Treatment of Psoriasis: A Double-Blind Multicenter Trial of Augmented Betamethasone Dipropionate Ointment in a Pulse Dose Treatment Regimen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A Double-Blind Study Comparing Oleum Horwathiensis with Placebo in the Treatment of Psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective cohort study of the cost of psoriasis treatment with topical corticosteroids versus topical calcipotriene

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Comparison of the response of psoriasis, over a 6-month period, to clobetasol propionate and fluocinolone acetonide ointments

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol. In the treatment of mild to moderate plaque psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

A cost-comparison study: Ulobetasol versus clobetasol in severe localized psoriasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005028.PUB2

7 January 2021

10.1002/14651858.CD005028.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3170919

OpenCitations bibliographic resource ID

3170919

1 reference